Harrow Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. (NASDAQ: HROW) on January 24, 2020. The report addresses a specific legal event under Item 8.01 (Other Events) rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a legal settlement and does not contain financial statements.
Material Changes
The primary material event is the resolution of a lawsuit filed in June 2019 by Anna Sue Gaukel and Lawrence Gaukel. The plaintiffs asserted class action allegations and product liability claims regarding the use of a compounded drug injection in the plaintiff's eyes. On January 24, 2020, the parties filed a joint stipulation, and the case was dismissed without prejudice. No economic consideration was exchanged between the parties.
Guidance, Outlook, and Risks
The filing states that the dismissal formally resolved all disputes between the parties connected to this matter. There is no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies beyond the closure of this specific litigation.
Investor Verification Checklist
- Confirm the dismissal of the Gaukel v. Harrow Health, Inc. case in Federal Court.
- Verify that no financial settlement or economic consideration was paid to the plaintiffs.
- Review the company's 10-K or 10-Q filings for the most recent comprehensive financial data, as this 8-K contains none.